Advanced searches left 3/3

Flecainide - DOAJ

Summarized by Plex Scholar
Last Updated: 07 August 2022

* If you want to update the article please login/register

Common Structural Pattern for Flecainide Binding in Atrial-Selective K v 1.5 and Na v 1.5 Channels: A Computational Approach

A combination blockade of Na vs. K vs. 1. 5 ion channels yielded a synergistic anti-arrhythmic effect with no changes in ventricles, according to theoretical models. As a first step toward potential multi-target directed ligand design strategies, we focused on K vs. 1. 5 and Na v 1. 5 to look for structural similarities in their binding site for flecainide. In a flecainide-B vs. 1. 5 docking model and a completed model of the flecainide-Na vs. 1. 5 complex, we discuss a computational workflow for a flecainide BS comparison in a flecainide-B vs. 1. 5 docking model and a solved structure of the flecainide-Na vs. 1. 5 complex.

Source link: https://doi.org/10.3390/pharmaceutics14071356


Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients: A crossover study of flecainide and pilsicainide

Defyne and prevent severe complications related to AF are among the treatment objectives of atrial fibrillation patients. This research compared the effectiveness of flecainide with pilsicainide in reducing the incidence of AF and improving quality of life in symptomatic paroxysmal AF patients without structural heart disease. Methods: The Atrial Fibrillation and Quality Of Life study, conducted as a prospective, multicenter, open-label crossover study comparing flecainide and pilsicainide as antiarrhythmic drug therapy. Results: There were 2 in the flecainide treatment group and 1 in the pilsicainide treatment group, respectively. During the first recurrence of AF during the efficacy phase, no significant difference was found between flecainide and pilsicainide therapies. Conclusions: There were no differences in AF frequency or QOL among symptomatic paroxysmal AF patients receiving flecainide or pilsicainide in this research.

Source link: https://doi.org/10.1016/j.joa.2017.03.005


Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular Cardiomyocytes.

We hypothesized that the potency of open-state RyR2 blockers such as flecainide and R-propafenone against Ca2+ waves in cardiomyocytes is determined by differences in RyR2 activity induced by CPVT mutations. We investigated Ca2+ sparks and waves in isolated saponin-permeabilized ventricular myocytes from two CPVT mouse models, wild-type mice, and WT rabbits using confocal microscopy. CPVT was significantly higher in CPVT with increased RyR2 expression, Ca2+ spark, and wave frequencies, which were significantly higher in CPVT relative to WT mouse myocytes. Both FLEC and RPROP inhibited Ca2+ waves with significantly higher potency and efficacy in CPVT relative to WT. FlEC and RPROP increased the potency of these permeabilized WT myocytes by caffeine exposure, but not of TET. Rabbi ventricular myocytes with higher Ca2+ spark rates than WT mouse ventricular myocytes were also significantly more potent in rabbit ventricular myocytes with intrinsically higher Ca2+ spark rates than WT mouse ventricular myocytes.

Source link: https://doi.org/10.1371/journal.pone.0131179


Flecainide challenge test: Predictors of unmasking of type 1 Brugada ECG pattern among those with non-type 1 Brugada ECG pattern

Prosk type 1 Brugada condition in these patients will help in determining Brugada Syndrome. Methods: We studied 29 patients, with clinical appearance suggestingive but not diagnostic of Brugada or with non-Type 1 Brugada pattern ECG. Group 1 u2013 FCT Positive among patients with no apparent Brugada ECG pattern, Group 1 u2013 FCT Negative, Group 2 u2013 FCT Negative, and Group 3 u2013 FCT Positive among patients with no spontaneous Brugada ECG pattern, according to the patient with non-type 1 Brugada ECG curve, Group 1 ;u2013 FCT Negative among patients with no spontaneous Brugada ECG pattern, Group 1 u2013 FCT Positive among patients with no one Brugada FCT pattern, Group 1 Brugada ECG pattern, Group 1 Brugada ECG pattern, Group 1 Brugada ECG pattern, Group 1 FCT Negative among patients with non-type 1 Brugada ECG pattern, Group 1 Brugada ECG pattern, Group 1 Brugada ECG despite Group 1 Brugada ECG pattern, Group 1 Brugada ECG pattern, Group 1 Brugada ECG –u2013 FCT Negative, efCT Negative, Group 1 Brugada FCT Neg The results of a binary logistic regression review found that family h/o SCD was a predictor of FCT positivity in Group 1. According to our report, family history of sudden cardiac death was the only predictor of flecainide test positivity among those with non-Type 1 Brugada patterns.

Source link: https://doi.org/10.1016/j.ipej.2016.06.001


Efficacy of Long-term Flecainide Therapy in Patients with Paroxysmal Atrial Fibrillation —Analysis Based on Time of Onset—

This review was designed to investigate the effectiveness of long-term flecainide therapy in maintaining sinus rhythms in patients with paroxysmal atrial fibrillation AF. A total of 70 patients, 54 men and 16 women were treated as an antiarrhythmic drug, according to the mean age of 65 years, which was a ten-years old. 00b1 10 years ago. The duration of sinus rhythm therapy in patients with diurnal and nocturnal paroxysmal AF was 32. 4 months to 20. 8 months, respectively; in patients with mixed paroxysmal AF, sinus rhythm therapy was only 7. 2 months; for patients with mixed paroxysmal AF, the duration of sinus rhythm maintenance was only 7. 2 months. U00b1 2. 1 months In the duration between diurnal and mixed cases, significant differences were noted. These results show that flecainide is particularly helpful in preventing AF recurrence in patients with diurnal paroxysmal AF.

Source link: https://doi.org/10.1016/S1880-4276(06)80005-0


An electrocardiographic series of flecainide toxicity

The Ic AADs of Vaughan-Williams refer to a class of drugs that block sodium channels, resulting in decreased conduction velocity of myocytes and Purkinje fibers, as well as reduced automaticity of pacemaker cells. Presented is a medical series of ECGs that occurred in a patient with flecainide toxicity.

Source link: https://doi.org/10.1016/j.ipej.2018.11.012


Flecainide intoxication in pediatric patients with supraventricular tachycardia

Flecainide, a class IC antiarrhythmic used in pediatric patients with no cardiac disease, is a class IC antiarrhythmic indicated for ventricular and supraventricular arrhythmias. In our hospital from 2017 to 2019, we present three consecutive cases of flecainide intoxication in children with supraventricular tachycardia. In patients with SVT, fluecainide intoxication may cause life-threatening illness. Following the start of therapy, and considering hospitalization for patients younger than 1 year old, we believe all children should be closely monitored with serial ECG and plasma levels of flecainide during the 48u201372h, which includes close monitoring for patients 1 year old.

Source link: https://doi.org/10.4103/apc.APC_116_19


Flecainide overdose – support using an intra-aortic balloon pump

Abstract Background Flecainide is an antiarrhythmic drug that is increasingly used for the treatment of super-ventricular arrhythmias. Case presentation A 47-year-old lady was admitted to the emergency department with severe central chest pains for a four-hour absence. With inotropic assistance, she improved over 48 hours, with both her QRS duration and left ventricular function returning to normal. Conclusions The use of an intra-aortic balloon pump is a useful relief device during the acute phase of flecainide overdose associated with severe myocardial depression.

Source link: https://doi.org/10.1186/1471-227X-5-10


Effect of flecainide on atrial fibrillatory rate in a large animal model with induced atrial fibrillation

Abstract Background: Arial fibrillatory cycle length has been used as one of the indices of atrial fibrillation during atrial fibrillation, and can be determined from surface ECG by computer-assisted estimation of atrial fibrillatory rate. Horses have been cited as a bona fide model for AF research because horses too, develop lone AF, but studies on AF characteristics in horses have yet to be published, but no data on AF complexity using surface ECG processing has been published. AFR of 295 fpm in the control group, with flecainide, 269 fpm in the control group, and 364 fpm in the horses with spontaneous persistent AF were seen at onset, at 295 u00b1 46 fibrillations per minute. AFR in horses with induced AF resembles AFR in humans with paroxysmal AF.

Source link: https://doi.org/10.1186/s12872-017-0720-1


Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload

Objectivity: The study argues that fluence in Casq22112/u2212C heterozygous mice, as well as other CPVT models, may have been mutation dependent. ObjectiveWe tried to find FLEC in Casq212/u2212C/u2212C+/u2212 cardiomyocytes and mice under similar conditions, raising the possibility that FLEC's response may be mutation dependent. Methods Following a 30 min u2212Mu221212 paraphrasedoutput:ResultsIn cardiomyocytes, FLEC's efficiency was also tested in vivo using either a low dose or a high dose catecholamine challenge. In both groups, CONclusionFLEC inhibits Ca2+ waves in RyR2R4496C+/u2212 cardiomyocytes, indicating that the RyR2 channel block by FLEC is not mutation-specific.

Source link: https://doi.org/10.3389/fphys.2019.00992

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions